Baumgart E, Völkl A, Hashimoto T, Fahimi H D
Department of Anatomy and Cell Biology, University of Heidelberg, Federal Republic of Germany.
J Cell Biol. 1989 Jun;108(6):2221-31. doi: 10.1083/jcb.108.6.2221.
Treatment of rats with a new hypocholesterolemic drug BM 15766 induces proliferation of peroxisomes in pericentral regions of the liver lobule with distinct alterations of the peroxisomal membrane (Baumgart, E., K. Stegmeier, F. H. Schmidt, and H. D. Fahimi. 1987. Lab. Invest. 56:554-564). We have used ultrastructural cytochemistry in conjunction with immunoblotting and immunoelectron microscopy to investigate the effects of this drug on peroxisomal membranes. Highly purified peroxisomal fractions were obtained by Metrizamide gradient centrifugation from control and treated rats. Immunoblots prepared from such peroxisomal fractions incubated with antibodies to 22-, 26-, and 70-kD peroxisomal membrane proteins revealed that the treatment with BM 15766 induced only the 70-kD protein. In sections of normal liver embedded in Lowicryl K4M, all three membrane proteins of peroxisomes could be localized by the postembedding technique. The strongest labeling was obtained with the 22-kD antibody followed by the 70-kD and 26-kD antibodies. In treated animals, double-membraned loops with negative catalase reaction in their lumen, resembling smooth endoplasmic reticulum segments as well as myelin-like figures, were noted in the proximity of some peroxisomes. Serial sectioning revealed that the loops seen at some distance from peroxisomes in the cytoplasm were always continuous with the peroxisomal membranes. The double-membraned loops were consistently negative for glucose-6-phosphatase, a marker for endoplasmic reticulum, but were distinctly labeled with antibodies to peroxisomal membrane proteins. Our observations indicate that these membranous structures are part of the peroxisomal membrane system. They could provide a membrane reservoir for the proliferation of peroxisomes and the expansion of this intracellular compartment.
用一种新的降胆固醇药物BM 15766处理大鼠,可诱导肝小叶中央周围区域的过氧化物酶体增殖,并使过氧化物酶体膜发生明显改变(鲍姆加特,E.,K. 施特格迈尔,F. H. 施密特,和H. D. 法希米。1987年。《实验医学杂志》56:554 - 564)。我们结合免疫印迹和免疫电子显微镜技术,利用超微结构细胞化学来研究这种药物对过氧化物酶体膜的影响。通过Metrizamide梯度离心法从对照大鼠和处理过的大鼠中获得了高度纯化的过氧化物酶体组分。用针对22-kD、26-kD和70-kD过氧化物酶体膜蛋白的抗体处理这些过氧化物酶体组分后制备的免疫印迹显示,BM 15766处理仅诱导了70-kD蛋白。在包埋于Lowicryl K4M的正常肝脏切片中,过氧化物酶体的所有三种膜蛋白都可以通过包埋后技术进行定位。用22-kD抗体获得的标记最强,其次是70-kD和26-kD抗体。在处理过的动物中,在一些过氧化物酶体附近发现了双膜环,其腔内过氧化氢酶反应呈阴性,类似于光滑内质网片段以及髓鞘样结构。连续切片显示,在细胞质中与过氧化物酶体有一定距离处看到的环总是与过氧化物酶体膜相连。双膜环对内质网标记物葡萄糖-6-磷酸酶始终呈阴性,但用过氧化物酶体膜蛋白抗体进行标记时则明显呈阳性。我们的观察结果表明,这些膜结构是过氧化物酶体膜系统的一部分。它们可以为过氧化物酶体的增殖和这个细胞内区室的扩张提供膜储备。